GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Genmab A/S (OCSE:GMAB) » Definitions » Debt-to-EBITDA

Genmab A/S (OCSE:GMAB) Debt-to-EBITDA : 0.15 (As of Mar. 2024)


View and export this data going back to 2000. Start your Free Trial

What is Genmab A/S Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genmab A/S's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr92 Mil. Genmab A/S's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2024 was kr918 Mil. Genmab A/S's annualized EBITDA for the quarter that ended in Mar. 2024 was kr6,892 Mil. Genmab A/S's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 was 0.15.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Genmab A/S's Debt-to-EBITDA or its related term are showing as below:

OCSE:GMAB' s Debt-to-EBITDA Range Over the Past 10 Years
Min: 0   Med: 0.07   Max: 0.14
Current: 0.14

During the past 13 years, the highest Debt-to-EBITDA Ratio of Genmab A/S was 0.14. The lowest was 0.00. And the median was 0.07.

OCSE:GMAB's Debt-to-EBITDA is ranked better than
82.12% of 274 companies
in the Biotechnology industry
Industry Median: 1.325 vs OCSE:GMAB: 0.14

Genmab A/S Debt-to-EBITDA Historical Data

The historical data trend for Genmab A/S's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Genmab A/S Debt-to-EBITDA Chart

Genmab A/S Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.06 0.05 0.10 0.08 0.13

Genmab A/S Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.76 0.12 0.07 0.21 0.15

Competitive Comparison of Genmab A/S's Debt-to-EBITDA

For the Biotechnology subindustry, Genmab A/S's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab A/S's Debt-to-EBITDA Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab A/S's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Genmab A/S's Debt-to-EBITDA falls into.



Genmab A/S Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Genmab A/S's Debt-to-EBITDA for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(90 + 680) / 5959
=0.13

Genmab A/S's annualized Debt-to-EBITDA for the quarter that ended in Mar. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(92 + 918) / 6892
=0.15

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Mar. 2024) EBITDA data.


Genmab A/S  (OCSE:GMAB) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.


Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.


Genmab A/S Debt-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Genmab A/S's Debt-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Genmab A/S (OCSE:GMAB) Business Description

Address
Kalvebod Brygge 43, Copenhagen, DNK, 1560
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab is also the creator of Tepezza for thyroid eye disease (partnered with Horizon) and Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), and Tivdak (partnered with Seagen) for cervical cancer. Genmab has several pipeline candidates targeting other oncologic indications.

Genmab A/S (OCSE:GMAB) Headlines

From GuruFocus

Top 5 2nd Quarter Trades of Lester Murray Antman dba SimplyRich

By GuruFocus Research GuruFocus Editor 07-22-2022